Publications by authors named "Simone Lasagni"

Claim this Profile
T
The tumor microenvironment of VETC+ hepatocellular carcinoma is enriched of immunosuppressive TAMs spatially close to endothelial cells.
Camilla De Carlo, Roy Rosman-Nathanson, Barbara Durante, Reha Akpinar, Cristiana Soldani, Simone Lasagni

Dig Liver Dis· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Neoangiogenic Transcriptomic Signature Impacts Hepatocellular Carcinoma Prognosis and Can Be Triggered by Transarterial Chemoembolization Treatment.
Rosina Maria Critelli, Federico Casari, Alberto Borghi, Grazia Serino, Cristian Caporali, Simone Lasagni

Cancers (Basel)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential Impact of Tumor Endothelial Angiopoietin-2 and Podoplanin in Lymphatic Endothelial Cells on HCC Outcomes with Tyrosine Kinase Inhibitor Treatment According to Sex.
Simone Lasagni, Rosina Maria Critelli, Fabiola Milosa, Dario Saltini, Filippo Schepis

Biomedicines· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Angiopoietin-2 and the Vascular Endothelial Growth Factor Promote Migration and Invasion in Hepatocellular Carcinoma- and Intrahepatic Cholangiocarcinoma-Derived Spheroids.
Adriana Romanzi, Fabiola Milosa, Gemma Marcelli, Rosina Maria Critelli, Simone Lasagni

Biomedicines· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GALAD outperforms aMAP and ALBI for predicting HCC in patients with compensated advanced chronic liver disease: A 12-year prospective study.
Erica Villa, Rossella Donghia, Valentina Baldaccini, Calogero C Tedesco, Endrit Shahini, Simone Lasagni

Hepatol Commun· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term SARS-CoV-2 Antibody Seroprevalence in Blood Donors, Italy.
Martina Ferrari, Lorenza Di Marco, Alessandra Pivetti, Stefania Paduano, Chiara Vecchi, Simone Lasagni

Emerg Infect Dis· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility, safety, and outcome of second-line nivolumab/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma.
Lorenza Di Marco, Alessandra Pivetti, Francesco Giuseppe Foschi, Roberto D'Amico, Filippo Schepis, Simone Lasagni

Liver Transpl· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upregulation of the oestrogen target gene SIX1 is associated with higher growth speed and decreased survival in HCV-positive women with hepatocellular carcinoma.
Rosina Maria Critelli, Fabiola Milosa, Adriana Romanzi, Simone Lasagni, Gemma Marcelli

Oncol Lett· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic Angiopoietin-2 Serum Level as Endothelial Damage Marker and Potential Therapeutic Target.
Gabriele Melegari, Rosina M Critelli, Simone Lasagni, Dante Romagnoli, Elisabetta Bertellini

Am J Pathol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after liver transplantation.
Simone Lasagni, Filippo Leonardi, Alessandra Pivetti, Lorenza Di Marco, Federico Ravaioli

Front Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19.
Erica Villa, Rosina Critelli, Simone Lasagni, Alessandra Melegari, Angela Curatolo

Blood Adv· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis